Clinical Trials
16 trialsNCT06304636 2025-11-24
DC15-MM-01
Cartesian Therapeutics
Phase 1 Terminated
NCT01997840 2025-03-04
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1/2 Terminated
NCT03582033 2024-12-24
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Terminated
NCT05113342 2024-11-12
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Phase 1 Terminated
NCT03755154 2024-10-16
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Phase 1 Terminated
NCT02978235 2024-09-05
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT00017433 2020-10-06
Arsenic Trioxide in Treating Patients With Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT00017069 2020-10-05
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT02369029 2016-03-09
BAY1238097, First in Man
Bayer
Phase 1 Terminated
NCT00431340 2015-07-08
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Valerio Therapeutics
Phase 2 Terminated
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00242827 2012-08-23
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00460460 2011-01-25
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
AstraZeneca
Phase 1 Terminated